GB Sciences, Inc.
GBLX · OTC
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | -0.00 | 0.20 | 0.06 |
| FCF Yield | -37.84% | -24.20% | -23.15% | -14.01% |
| EV / EBITDA | -3.05 | -4.80 | -5.60 | -10.67 |
| Quality | ||||
| ROIC | 39.97% | 55.52% | 469.60% | -31.42% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.72 | 0.37 | 2.04 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | -100.00% |
| Free Cash Flow Growth | 37.40% | 24.57% | 16.62% | 48.09% |
| Safety | ||||
| Net Debt / EBITDA | -1.23 | -0.80 | -0.64 | -1.83 |
| Interest Coverage | -6.49 | -9.36 | -3.94 | -1.56 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,177,415.13 | -11,736.95 | -8,580.30 | -10,887.33 |